Skip to Main content Skip to Navigation
Journal articles

Management of elderly patients with chronic lymphocytic leukemia in the era of targeted therapies

Abstract : Chronic lymphocytic leukemia (CLL) is frequently diagnosed after 71 years, though median age in published clinical trials with standard chemoimmunotherapy regimens in frontline or relapse setting is mostly below 70 years (58-71 years). Development of oral, less toxic and thus more affordable targeted therapies offers new therapeutic options in those patients deemed unfit for chemotherapy.Recent findingsThis review will discuss results of these new agents in the therapy of elderly patients. Apart from discussing the impact of chronological age, creatinine clearance and cumulative illness rating scale scores in the clinical outcomes, we will also discuss how individualized treatment decision-making should include more precise geriatric assessment tools to thoroughly assess life expectancy, anticipate tolerability, to avoid deleterious stress precipitating prefrail patients into definitive loss of capacity, with dramatic social and economic costs.SummaryIn the era of new targeted agents to fight cancers, we propose concepts to help us understand how elderly dedicated trial designs and geriatric assessment tools (apart from the evaluation of CLL biological risk factors) will undoubtedly revolutionize therapeutic approaches in everyday practice CLL patients.
Document type :
Journal articles
Complete list of metadata
Contributor : NGERE UL Connect in order to contact the contributor
Submitted on : Thursday, January 11, 2018 - 11:56:48 AM
Last modification on : Wednesday, June 1, 2022 - 5:09:14 AM



Loic ysebaert, Pierre Feugier, Anne-Sophie Michallet. Management of elderly patients with chronic lymphocytic leukemia in the era of targeted therapies. Current Opinion in Oncology, Lippincott, Williams & Wilkins, 2015, 27 (5), pp.365 - 370. ⟨10.1097/CCO.0000000000000213⟩. ⟨hal-01681034⟩



Record views